Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration

Abstract

Purpose In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using intravitreal ziv-aflibercept. Our purpose is to ascertain the 3-month safety and efficacy in wet age-related macular degeneration (AMD) treated with intravitreal ziv-aflibercept. Methods Prospectively, consecutive patients with wet AMD underwent ziv-aflibercept intravitreal injection (1.25mg/0.05mL) from March 2015 to November 2015. Monitoring of best-corrected visual acuity, intraocular inflammation, cataract progression and by spectral domain optical coherence tomography were carried out at baseline day 1, 1week, 1month, 2months and 3months after injections. Results 30 eyes were treated (22 Caucasians, 8 Indians; 16 men, 14 women; 14 right eyes and 16 left eyes) with mean age of 74.3years with 11 treatment-naïve cases and 19 having had treatment-non-naïve. Best-corrected visual acuity improved from baseline logMAR 1.08-0.74 at 1week, 0.72 at 1month, 0.67 at 2months and 0.71 at 3months (p<0.001 for all time periods). Central macular thickness in microns decreased from 332.8 to 302.0 at 1week, 244.8 at 1month, 229.0 at 2months and 208.2 at 3months (p<0.001 for all time periods). There were no signs of intraocular inflammation, or change in lens status or increase in intraocular pressure throughout the study. Conclusions Off label use of ziv-aflibercept improves visual acuity, without detectable ocular toxicity and offers a cheaper alternative to the same molecule aflibercept, especially in low/middle-income countries and in countries where aflibercept (Eylea) is not available. © Published by the BMJ Publishing Group Limited.